Reference

Metabolite of quetiapine

Some chemicals with cas registry numbers like 111974-74-4 and 5747-48-8 are also used. Metabolite of quetiapine. (Astrazeneca AB; Astrazeneca UK Limited; Goldstein, Jeffrey, Swed.). PCT Int. Appl. WO 2005002586 A1 13 Jan 2005, 16 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-554. ICS: A61P025-18. APPLICATION: WO 2004-GB2783 28 Jun 2004. PRIORITY: US 2003-2003/PV484365 2 Jul 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 28, 63 A method of treating anxiety, agitation, hostility, panic, eating disorders, affective symptoms, mood symptoms, neg. and pos. psychotic symptoms commonly assocd. with schizophrenia, dementia, anxiety, depression, mood disorders, bipolar disorders, bipolar mania, bipolar depression, cognitive disorders and neurodegenerative disorders comprising administering an effective amt. of the dibenzothiazepine (quetiapine metabolite) or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical compn. is provided comprising an effective amt. of the dibenzothiazepine or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent. Synthesis of the dibenzothiazepine and its dihydrochloride salt is included. .